Physician profile
Jinglu Li
NPI 1548864796
$5,327.40
in general payments reported to CMS, 2019-2025
18 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.69 · 2022: $416 · 2023: $734 · 2024: $2,013 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,656 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,656.24 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,172.73 | 2021-2025 | |
| Janssen Biotech, INC. | $1,326.43 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $314.41 | 2024-2025 | Entyvio |
| Lilly USA, LLC | $295.91 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Gilead Sciences, INC. | $250.00 | 2022-2024 | Epclusa |
| Intra-Sana Laboratories | $200.00 | 2022 | |
| Merck Sharp & Dohme LLC | $145.35 | 2022-2023 | Dificid, Vaxneuvance, Pneumovax 23 |
| Amgen INC. | $144.22 | 2023 | Evenity, Prolia |
| Qol Medical, LLC | $138.62 | 2025 | Sucraid |
| Janssen Scientific Affairs, LLC | $85.58 | 2024-2025 | Tremfya, Stelara |
| Veloxis Pharmaceuticals, INC. | $67.89 | 2025 | Envarsus |
| Exact Sciences Corporation | $44.69 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $43.14 | 2024 | |
| Celgene Corporation | $33.22 | 2024 | Zeposia |
| Ardelyx, INC. | $21.97 | 2025 | Ibsrela |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $17.19 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.15 | 2024 | Xifaxan |
| Phadia US INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinglu Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.